# Merantix Capital

> Merantix Capital is a VC fund backing Artificial Intelligence. See 31 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Berlin, Germany
- Total investments: 31
- Last investment: Jun 2026
- Lead investor: 58%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/7943887
- X (Twitter): https://twitter.com/merantix
- Website: http://merantix.com
- Facebook: https://www.facebook.com/merantix

Merantix Capital is a VC fund in Berlin focused on Artificial Intelligence and Machine Learning. At Merantix Venture Studio we ideate, build and scale AI companies. Through our unique incubation platform, seed financing and exceptional teams of entrepreneurs and engineers, we transfer world-leading research into ventures that will disrupt existing and create new industries.

## Contacts

5 contacts available for Merantix Capital. Shizune tracks 4 team members at Merantix Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/merantix?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $4.3M–$6.6M |
| Pre-Seed | $1.1M–$3.5M |
| Series A | $4.5M–$19M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Artificial Intelligence | 9 | 29% |
| Machine Learning | 6 | 19% |
| Software | 3 | 10% |
| Analytics | 3 | 10% |
| Health Care | 3 | 10% |

36 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Pre-Seed | 12 | 39% |
| Seed | 10 | 32% |
| Series A | 2 | 6% |
| Funding Round | 1 | 3% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 14 | 45% |
| Switzerland | 1 | 3% |
| United Kingdom | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Adrian Locher | Founder, CEO and General Partner | 10 | https://shizune.co/investors/profile/adrian-locher |
| Janette Wiget | Chief Financial Officer | 1 | https://shizune.co/investors/profile/janette-wiget-509e |
| Rasmus Rothe | Founder | 4 | https://shizune.co/investors/profile/rasmus-rothe |
| Sona Chandra | Founder | 0 | https://shizune.co/investors/profile/sona-chandra |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Almetra | AI-based process analytics platform to increase productivity and quality in manual processes. Processes are captured using computer vision and automatically analysed with a highly flexible AI to identify improvement potential.1. Real-time capture with cameras Cameras are installed at individual assembly stations capturing live video streams ofassembly or packaging tasks.2. AI tracks material & work steps Video streams are continuously analyzed to detect workpiece movements, cycle times, and work step sequencing.3. Aggregation for data analysis Process data is aggregated per article and production to provide insights on process performance. Video snippets allow for a comprehensive root-cause analysis.4. Data-driven improvements Your factory managers and process engineers define, implement and measure process improvements to increase productivity and quality in your assembly line. | $18.5M | Series A | Jun 25, 2026 |  |
| Graph Therapeutics | Graph is a precision immunology techbio that leverages perturbation modeling from primary patient cell samples combined with multi-omics data to deliver transformative targeted therapies and biomarkers for immune-driven diseases. Graph believes that due to an incomplete understanding of complex immune-mediated diseases, millions of people are leftwithout adequate treatment options - and AI trained with complex disease data can solve this. | $5M | Seed | Jun 22, 2026 |  |
| WhyBrilliant | WhyBrilliant operates as a B2B platform marketplace that utilizes conversational voice artificial intelligence to automate job matching. The company's core business model reverses the traditional hiring framework by having pre-vetted corporate clients submit inquiries to anonymized, AI-screened talent. Its consumer value proposition centers oneliminating standard application forms and manual recruiter screenings by deploying an AI assistant to privately map candidate objectives and facilitate secure introductions. This structural approach enables employers to optimize their hiring pipeline efficiency while guaranteeing job seekers profile confidentiality from current employers. | $1.2M | Pre-Seed | Jun 16, 2026 |  |
| OutPost Bio | OutPost Bio aims to unlock new ways to design drugs, ingredients, and consumer health products by boosting its experimental and modelling platforms. | $3.5M | Pre-Seed | Mar 02, 2026 |  |
| FICUS HEALTH | FICUS HEALTH is a Berlin-based company that automates documentation using AI-based software. |  | Seed | Dec 11, 2025 |  |
| Arqh | Arqh is a decision intelligence engine that converts your business objectives into real-time operational decisions. | $3.8M | Pre-Seed | Sep 30, 2025 |  |
| revel8 | revel8 (formerly Company Shield) helps organizations stop GenAI-powered social engineering attacks with real-time, personalized simulations across email, SMS, chat, voice, and video. The AI-driven platform mirrors real attack tactics, adapts to each user’s risk profile, and reinforces awareness through gamified, habit-forming training. | $6.6M | Seed | Sep 25, 2025 |  |
| Droidrun | Droidrun is a cutting-edge software development company that specializes in creating innovative solutions enabling AI agents to seamlessly access and control smartphone applications. By leveraging advanced artificial intelligence and machine learning algorithms, their software facilitates smooth interactions between AI systems and mobile devices,empowering agents to autonomously navigate, operate, and optimize a wide range of apps on both Android and iOS platforms. | $2.5M | Pre-Seed | Jul 23, 2025 |  |
| Graph Therapeutics | Graph is a precision immunology techbio that leverages perturbation modeling from primary patient cell samples combined with multi-omics data to deliver transformative targeted therapies and biomarkers for immune-driven diseases. Graph believes that due to an incomplete understanding of complex immune-mediated diseases, millions of people are leftwithout adequate treatment options - and AI trained with complex disease data can solve this. | $3.1M | Pre-Seed | Jan 09, 2025 |  |
| Briink | Briink leverages AI to automate the workflows of sustainable finance teams | $4.3M | Seed | Sep 30, 2024 |  |

10 of 31 investments shown.

## Co-investors
- [Alpha Intelligence Capital](https://shizune.co/investors/profile/alpha-intelligence-capital) — VC Fund, 6 deals together
- [Ananda Impact Ventures](https://shizune.co/investors/profile/ananda-ventures-gmbh-social-venture-fund) — VC Fund, 4 deals together
- [NAP](https://shizune.co/investors/profile/nap-vc) — VC Fund, 3 deals together
- [Robin Capital](https://shizune.co/investors/profile/robin-capital) — VC Fund, 3 deals together
- [Underline Ventures](https://shizune.co/investors/profile/underline-ventures) — VC Fund, 3 deals together
- [Better Angle](https://shizune.co/investors/profile/better-angle) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund

### Similar country
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund
- [HV Capital](https://shizune.co/investors/profile/holtzbrinck-ventures) — VC Fund
- [IBB Ventures](https://shizune.co/investors/profile/ibb) — VC Fund

## Featured in investor lists
- [Artificial intelligence Investors in Germany](https://shizune.co/investors/artificial-intelligence-investors-germany)
- [Artificial intelligence VC Funds in Germany](https://shizune.co/investors/artificial-intelligence-vc-funds-germany)
- [Machine Learning Investors in Germany](https://shizune.co/investors/machine-learning-investors-germany)
- [Machine Learning VC Funds in Germany](https://shizune.co/investors/machine-learning-vc-funds-germany)
- [Health Care VC Funds in Germany](https://shizune.co/investors/health-care-vc-funds-germany)
- [Health Care Investors in Germany](https://shizune.co/investors/health-care-investors-germany)

## FAQ

### What does Merantix Capital invest in?

Merantix Capital invests primarily in Artificial Intelligence, Machine Learning and Software startups, most often at Pre-Seed and Seed stage. Most of the 31 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Merantix Capital's check size?

Merantix Capital typically joins rounds of $4.3M–$6.6M at Seed, $1.1M–$3.5M at Pre-Seed and $4.5M–$19M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Merantix Capital participates in.

### How do I contact Merantix Capital?

Public channels for Merantix Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Merantix Capital?

The team at Merantix Capital includes Adrian Locher (Founder, CEO and General Partner), Janette Wiget (Chief Financial Officer) and Rasmus Rothe (Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co